#ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approval

MUNICH — Cytokinetics’ heart drug Myqorzo could gain expanded approval next year, potentially doubling its market reach, after detailed results backed the drug’s use in a heart muscle disease. The new data, presented at the European ...